Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Catalytica Expects GMP Problems To Be Resolved During Latter Half Of 2002

Executive Summary

DSM Catalytica expects to resolve all GMP problems at its Greenville, N.C. facility in the second half of 2002

You may also be interested in...



DSM Submits “Final” GMP Report To FDA; New Quality Systems In Place

DSM Pharmaceuticals is highlighting new environmental monitoring systems in its response to FDA about recent good manufacturing practices inspections

DSM Submits “Final” GMP Report To FDA; New Quality Systems In Place

DSM Pharmaceuticals is highlighting new environmental monitoring systems in its response to FDA about recent good manufacturing practices inspections

GSK Tabloid Shortage Due To Catalytica Problems; Emergency Ordering Set Up

GlaxoSmithKline is supplying Tabloid on an emergency basis through pharmacies while the acute nonlymphocytic leukemia product is in short supply

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS039321

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel